Regeneron Pharmaceuticals Inc banner

Regeneron Pharmaceuticals Inc
XBER:RGO

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
XBER:RGO
Watchlist
Price: 128.94 EUR 0.71% Market Closed
Market Cap: €13.9B

Relative Value

RGO price has not been updated for more than 10 years. This may indicate that the stock has been delisted.

The Relative Value of one RGO stock under the Base Case scenario is hidden EUR. Compared to the current market price of 128.94 EUR, Regeneron Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RGO Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

RGO Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
XBER:RGO
77.5B EUR 5.4 17.2 12.6 14.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
362.5B USD 5.9 86.6 14.4 20
US
Amgen Inc
NASDAQ:AMGN
187.5B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
170.3B USD 5.8 20 12.5 15.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.6 29.2 21.9 22.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
AU
CSL Ltd
ASX:CSL
66.8B AUD 3.1 33.9 11.2 14.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 11.1 131.9 73.8 82
NL
argenx SE
XBRU:ARGX
36.1B EUR 10.2 32.8 35.3 36.1
P/S Multiple
Revenue Growth P/S to Growth
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average P/S: 3 063 003.7
5.4
10%
0.5
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
11.1
34%
0.3
NL
argenx SE
XBRU:ARGX
10.2
27%
0.4
P/E Multiple
Earnings Growth PEG
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average P/E: 47
17.2
13%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.6
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
AU
CSL Ltd
ASX:CSL
33.9
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
131.9
84%
1.6
NL
argenx SE
XBRU:ARGX
32.8
32%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average EV/EBITDA: 24.5
12.6
18%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
73.8
67%
1.1
NL
argenx SE
XBRU:ARGX
35.3
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Regeneron Pharmaceuticals Inc
XBER:RGO
Average EV/EBIT: 27.4
14.4
23%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
AU
CSL Ltd
ASX:CSL
14.1
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
82
69%
1.2
NL
argenx SE
XBRU:ARGX
36.1
51%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett